ACE2 and COVID-19: ACE2 is present in various organs, including the cardiovascular system, and its decreased availability due to COVID-19 reduces its cardiovascular protective effects.[10] Another potential mechanism is the incorporation of the SARS-CoV-2 genome into the DNA of infected human cells, which leads to the sustained activation of the immune and inflammation-mediated coagulation cascade.